Qifang Zhang, Jamie L Sturgill, Maciej Kmieciak, Karol Szczepanek, Marta Derecka, Catherine Koebel, Laura J Graham, Yun Dai, Shuang Chen, Steven Grant, Joanna Cichy, Kazuya Shimoda, Ana Gamero, Masoud Manjili, Harry Bear, Daniel Conrad, Andrew C Larner
The antigrowth and immunomodulatory actions of interferons (IFNs) have enabled these cytokines to be used therapeutically for the treatment of a variety of hematologic and solid malignancies. IFNs exert their effects by activation of the Jak/Stat signaling pathway. IFNγ stimulates the tyrosine kinases Jak1 and Jak2, resulting in activation of the Stat1 transcription factor, whereas type 1 IFNs (IFNα/β) activate Jak1 and Tyk2, which mediate their effects through Stat1 and Stat2. Disruption in the expression of IFNγ, IFNα receptors, or Stat1 inhibits antitumor responses and blunt cancer immunosurveillance in mice...
September 2011: Journal of Interferon & Cytokine Research